ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Physician Assistant, Medical

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,861Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 76

$400K Total Retail Price of All Prescriptions

Rank: 4 out of 76

386 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 386 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

12% of this provider’s 386 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

2% of this provider’s 7,880 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 442 409 1 1
SYNTHROID 275 251 2 26
SIMVASTATIN 270 270 3 3
LISINOPRIL 258 231 4 5
METOPROLOL TARTRATE 253 237 5 11
AMLODIPINE BESYLATE 246 220 6 4
OMEPRAZOLE 223 209 7 2
CITALOPRAM HBR 209 170 8 19
FUROSEMIDE 195 187 9 8
POTASSIUM CHLORIDE 180 149 10 13
WARFARIN SODIUM 177 141 11 6
HYDROCODONE-ACETAMINOPHEN 163 129 S3 12 7
METOPROLOL SUCCINATE 131 130 13 10
ZOLPIDEM TARTRATE 115 109 14 23
TRAMADOL HCL 112 98 15 14
METFORMIN HCL 107 104 16 9
ALLOPURINOL 99 92 17 30
PREDNISONE 92 85 18 27
TRAZODONE HCL 91 73 19 46
SERTRALINE HCL 87 83 20 22
ALENDRONATE SODIUM 86 72 21 20
CLONIDINE HCL 84 84 22 54
LOSARTAN POTASSIUM 80 80 23 18
TAMSULOSIN HCL 78 78 24 34
NAMENDA 76 76 25 50
BUMETANIDE 74 72 26 43
PRAMIPEXOLE DIHYDROCHLORIDE 74 74 26 75
GABAPENTIN 70 61 28 16
DONEPEZIL HCL 69 69 29 60
PROAIR HFA 68 56 30 47
DIGOXIN 67 67 31 63
HYDROCHLOROTHIAZIDE 66 66 32 12
FENTANYL 64 51 S2 33 40
ATENOLOL 64 63 33 15
LANTUS 63 51 35 32
TERAZOSIN HCL 62 62 36 83
IBUPROFEN 60 53 37 53
METHYLPREDNISOLONE 59 52 38 88
LISINOPRIL-HYDROCHLOROTHIAZIDE 58 53 39 29
PANTOPRAZOLE SODIUM 58 47 39 41
NEXIUM 55 37 41 52
SPIRIVA 54 49 42 33
BUSPIRONE HCL 50 41 43 99
ENALAPRIL MALEATE 50 39 43 31
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 7, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.